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ABSTRACT 20 
Burkholderia pseudomallei, the causative agent of melioidosis, has a complex and poorly 21 
understood extracellular and intracellular lifestyle. We used transposon insertion-site 22 
sequencing (TraDIS) to retrospectively analyze a transposon library that had previously been 23 
screened through a Balb/c mouse model to identify genes important for growth and survival in 24 
vivo. This allowed us to identify the insertion sites and phenotypes of negatively selected 25 
mutants that were previously overlooked due to technical constraints. All 23 unique genes 26 
identified in the original screen were confirmed by TraDIS and an additional 105 mutants were 27 
identified with varying degrees of attenuation in vivo. Five of the newly identified genes were 28 
chosen for further characterization and clean, unmarked deletion mutants of bpsl2248, tex, 29 
rpiR, bpsl1728 and bpss1528 were constructed in the wild-type strain K96243. Each of these 30 
mutants was tested in vitro and in vivo to confirm their attenuated phenotypes and investigate 31 
the nature of the attenuation. Our results confirm that we have identified new genes important 32 
to in vivo virulence with roles in different stages of B. pseudomallei pathogenesis including 33 
extracellular and intracellular survival. Of particular interest, deletion of the transcription 34 
accessory protein Tex was shown to be highly attenuating and the tex  mutant was capable of 35 
providing protective immunity against challenge with wild-type B. pseudomallei, suggesting 36 
that the genes identified in our TraDIS screen have the potential to be investigated as live 37 
vaccine candidates. 38 
  39 
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INTRODUCTION 40 
Burkholderia pseudomallei is a gram-negative, motile saphrophytic bacterium that is 41 
the causative agent of melioidosis. This emerging human pathogen is endemic to the soil and 42 
water of tropical areas including Thailand, Singapore, and northern Australia and can cause 43 
infection through contact with broken skin or through ingestion or inhalation of the bacterium 44 
(1). The resulting disease can manifest as a localized skin ulcer or can progress to a systemic 45 
infection that is associated with mortality rates as high as 50% in some endemic regions 46 
(2)There is currently no licensed vaccine available against B. pseudomallei and it is highly 47 
resistant to most antibiotics, severely limiting treatment options (3). Due to the virulent nature 48 
of the pathogen, potential for aerosol transmission, and lack of therapeutic options, B. 49 
pseudomallei is listed as a Tier 1 bioterrorism threat by the Centers for Disease Control and 50 
Prevention (4).  51 
B. pseudomallei is a facultative intracellular pathogen capable of invading and 52 
replicating within both epithelial cells and macrophages (5) While B. pseudomallei is capable 53 
of extracellular growth and survival and is highly resistant to complement-mediated killing in 54 
human sera, intracellular growth is essential for virulence (2, 6) When B. pseudomallei enters 55 
the host cell, either through phagocytosis or by inducing its own uptake into non-phagocytic 56 
cells, it is able to escape from the phagosome or endocytic vacuole into the cell cytoplasm 57 
(7). There, B. pseudomallei is able to exploit the host cell cytoskeleton by inducing actin 58 
polymerization at one pole of the bacterium, forming actin comet tails which propel the 59 
bacteria through the cytoplasm and forming membrane protrusions into adjacent cells, 60 
facilitating cell-to-cell spread (8). Unique among bacterial pathogens that polymerize actin for 61 
motility, B. pseudomallei is capable of inducing cell fusion upon contact with neighboring cells, 62 
resulting in the formation of multinucleated giant cells (MNGCs) that can contain up to 63 
hundreds of nuclei (9). 64 
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        This complex intracellular lifestyle is regulated by a number of virulence factors 65 
encoded within the large 7.25 megabase B. pseudomallei genome including three type III 66 
secretion systems (T3SS), six type VI secretion systems (T6SS), multiple polysaccharide loci, 67 
and a number of secreted effectors (10). The B. pseudomallei polysaccharide capsule and 68 
lipopolysaccharide (LPS) help the bacteria survive extracellularly and resist complement 69 
deposition(2, 11, 12),while the Bsa T3SS has been implicated in helping B. pseudomallei 70 
induce uptake into non-phagocytic cells, escape the vacuole, and resist killing by autophagy 71 
(13, 14). In addition, actin polymerization has been shown to be mediated by the 72 
autotransporter BimA, which is expressed on one pole of the bacteria and stimulates the 73 
formation of new actin filaments (15, 16) Finally, the T6SS-1 is required for cell fusion and the 74 
formation of MNGCs (17, 18) 75 
The identification and characterization of these important virulence factors has greatly 76 
improved our understanding of B. pseudomallei pathogenesis. However, much remains poorly 77 
understood and the vast majority of B. pseudomallei virulence factors remain to be identified. 78 
One technique that has been highly successful at identifying genes that are required for the in 79 
vivo virulence of many bacterial species has been the application of large-scale forward 80 
genetic screens using libraries of bacterial transposon insertion mutants (19-24). We have 81 
previously successfully applied this strategy to the study of B. pseudomallei using an 82 
approach known as signature tagged mutagenesis (STM) in which pools of mutants each 83 
containing a unique tag are used to infect an animal model (25, 26). By comparing the 84 
population of mutants present in infected animals (output pools) to the original pool of mutants 85 
used to infect the animals (input pools), it is possible to identify mutants that are unable to 86 
survive and grow in vivo. Rhis method identified the B. pseudomallei capsule and the 87 
branched chain amino acid synthase ilvE as essential for in vivo survival, which led to the 88 
development of an ilvE mutant as a live attenuated vaccine candidate.  A number of additional 89 
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virulence factors have also been identified by this method, the majority of which are predicted 90 
to be involved in metabolism and replication (25, 26). However, these studies were 91 
constrained by technical limitations regarding library size and lacked the sensitivity to 92 
distinguish mild attenuation phenotypes. While microarray technology was used to identify 93 
mutants negatively selected in the output pools, the insertion site of each mutant needed to 94 
be identified individually using a difficult and time-consuming PCR approach. As a result, only 95 
the most strongly attenuated mutants were followed up to determine the gene of interest. 96 
More recently, the development of next-generation sequencing technology has 97 
resulted in the development of transposon library sequencing techniques known as 98 
transposon insertion-site sequencing (TraDIS) and tn-seq that allow entire libraries to be 99 
screened and all insertion sites identified quickly and easily. This technique has been applied 100 
to large bacterial libraries to identify every essential gene within the genome and to identify 101 
new in vivo virulence factors (27, 28). It can also be retrospectively applied to previously 102 
screened STM libraries to identify the insertion sites and phenotypes of mutants that were 103 
previously overlooked due to technical constraints, allowing the identification of new virulence 104 
factors without undertaking further animal experiments (29) Here we describe the retroactive 105 
sequencing of a B. pseudomallei K96243 STM library that we previously screened through an 106 
in vivo mouse model (26). Using this improved technique we were able to identify many new 107 
potential virulence factors and overcome biases that had constrained the original screen 108 
without the requirement for further animal experiments. Moreover, we were able to identify 109 
mutants with intermediate phenotypes that would otherwise have been overlooked. We 110 
selected five of these newly-identified mutants for additional characterization and created 111 
clean unmarked deletion mutants for each gene of interest. We then confirmed the in vivo 112 
growth and survival defect identified in our screen and examined the ability of each mutant to 113 
enter and replicate within epithelial cells and macrophages and complete the B. pseudomallei 114 
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intracellular lifecycle as well as survive extracellular sera killing. We found that each of these 115 
mutants was attenuated to varying degrees, confirming that we have identified new genes 116 
with important roles in different stages of B. pseudomallei pathogenesis and increasing our 117 
understanding of this important human pathogen.  118 
 119 
MATERIALS AND METHODS 120 
Bacterial strains and culture conditions 121 
B. pseudomallei strain K96243, a clinical isolate from Thailand was used for the construction 122 
of the STM library and for each of the individual mutants . Escherichia coli 19851 (pir+) was 123 
used for direct conjugation in the construction of the STM library, and E. coli MFDpir was 124 
used for conjugation in the construction of individual mutants (30). All experiments were 125 
performed in Luria-Bertani (LB) broth or agar at 37°C, and E. coli MFDpir cells were also 126 
supplemented with 0.3 mM diaminopimelic acid (DAP). When necessary plates and cultures 127 
were supplemented with antibiotics at the following concentrations: 100 µg/mL Zeocin (Life 128 
Technologies), 400 µg /mL kanamycin, 100 µg /mL ampicillin. 129 
Genomic DNA Extraction 130 
10 mL of overnight shaken cultures was spun down at 4000 RPM in a bench top centrifuge 131 
and resuspended in 10 mL of lysis buffer (100 µg/mL proteinase K, 10 mL NaCL, 20 mL Tris 132 
HCl pH8, 1 mM EDTA, 0.5% SDS). 3 mL of sodium perchlorate was added to the solution and 133 
incubated for 1 hour at room temperature. Genomic DNA was isolated using a 134 
phenol:chloroform:isoamyl alcohol extraction (25:24:1), precipitated with ethanol and spooled 135 
into deionised water.  136 
Illumina Sequencing 137 
Approximately 5 μg of genomic DNA from each of the input, lung and spleen samples was 138 
fragmented to ~300 bp by sonication in a BioRupter. The fragmented DNA was end repaired 139 
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and A-tailed using the NEBNext DNA library preparation reagent kit for Illumina (NEB). 140 
Annealed adapters Ind_Ad_T(ACACTCTTTCCCTACACGACGCTCTTCCGATC*T,  141 
* indicates phosphorothioate) and 142 
Ind_Ad_B(pGATCGGAAGAGCGGTTCAGCAGGAATGCCGAGACCGATCTC) were ligated 143 
onto the samples. PCR was performed using primers 144 
PE_PCR_V3.3(CAAGCAGAAGACGGCATACGAGATCGGTACACTCTTTCCCTACACGACG145 
CTCTTCCGATC) and 146 
MnTn5_P5_3pr_3(AATGATACGGCGACCACCGAGATCTACACCTAGGCtGCGGCtGCACTT147 
GTG), which include flow cell binding sites. The PCR program used was 2 minutes at 94°C, 148 
22 cycles of (30 s at 94°C, 20 s at 65°C and 30 s at 72°C), and 10 minutes at 72°C. They 149 
were then size selected to between 200-400 bp in a 2% agarose gel made up with 1xTBE 150 
buffer, with purification by Qiagen Gel Extraction kit. The final concentration of the samples 151 
were checked by both BioAnalyzer and qPCR. Preparation products were sequenced on an 152 
Illumina Hi-Seq 2000 as 36 bp single-end reads. Concentration of the samples was 153 
established using qPCR with the primers Syb_FP5(ATGATACGGCGACCACCGAG) and   154 
Syb_RP7(CAAGCAGAAGACGGCATACGAG). They were then size selected to between 300-155 
500 bp in a 2% agarose gel made up with 1xTBE buffer, with purification by Qiagen Gel 156 
Extraction kit. The final concentration of the samples were checked by both BioAnalyzer and 157 
qPCR. Preparation products were sequenced on an Illumina Hi-Seq 2000 as 100 bp single-158 
end reads. 159 
Bioinformatic and statistical analysis 160 
Raw reads that passed quality control filters and contained the transposon were mapped onto 161 
the B. pseudomallei K96243 reference genome (version 6) using bowtie (version 2-1.0)  162 
allowing for zero mismatches, and excluding non-uniquely mapped reads. The SAMtools 163 
toolkit (samtools.sourceforge.net) was applied to the alignment files to determine insertion 164 
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sites and coverage. For differential expression analysis, the coverage values were variance-165 
stabilized using an arcsine-root transformation , and log2 ratios between the input pools and 166 
the lung and spleen samples were calculated. Minimum starting values of 200 sequencing 167 
reads within the input pool were used to ensure sufficient starting quantities for negative 168 
selection analysis and avoid background. To define negative selection, cut-offs of the lowest 169 
2.5% of log2 ratios within the spleen pool comparisons and the lowest 5% of ratios within the 170 
lung pool comparisons were set based on the mean distribution of the log2 fold change. 171 
Generation of clean deletion mutants 172 
Unmarked deletion mutants were constructed as has been previously described using the 173 
suicide vector pDM4 (31). Briefly, 600-1000 bp regions flanking each gene of interest were 174 
amplified with an XbaI restriction site on the 5’ end and overlapping sequences on the 3’ end 175 
of the PCR product using Phusion High-Fidelity PCR master mix (ThermoScientific). The 176 
resulting products were then spliced together using splicing by overlapping extension PCR 177 
(SOE PCR) to generate a full-length product consisting of the upstream and downstream 178 
flanks lacking the target gene. This product was then cloned into the intermediate plasmid 179 
pGEM-T and then subcloned into pDM4 using XbaI. The resulting mutagenesis construct was 180 
then introduced into E. coli MFDpir cultured in LB media containing 0.3 mM DAP, and then 181 
transferred into B. pseudomallei K96243 by direct mating. Merodiploids containing the 182 
integrated plasmid were selected for on LB agar containing 30 μg/ml chloroamphenicol, and 183 
screened using primers designed against the gene of interest. Successful clones were then 184 
plated onto high-sucrose agar (10 g/L tryptone, 5 g/L yeast extract, 100 g/L sucrose) and 185 
grown for 48-72 hours at 24°C. Colonies were screened for sensitivity to chloroamphenicol 186 
due to loss of the pDM4 cassette, as well as by PCR using primers designed against the gene 187 
of interest and across the deletion junction. The resulting mutants were confirmed by full 188 
genome sequencing using an Illumina MiSeq sequencer to confirm the loss of pDM4 and the 189 
 o
n
 January 8, 2019 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
 Page 9 
null mutation. The primers used for mutagenesis and screening the resulting clones are listed 190 
in Supplemental Table 2.  191 
Mouse infections 192 
Female BALB/c mice (Charles Rivers Laboratories International, INC, Kent, UK) aged 193 
between 6-8 weeks were used.   Mice were housed under specific pathogen-free conditions, 194 
with free access to food and water.  All animal experiments were performed in accordance 195 
with the Animals (Scientific Procedures) Act of 1986 and the local Ethical Review Committee, 196 
under animal biohazard Containment Level 3 conditions (CL3).  For infections, aliquots of B. 197 
pseudomallei K96243 mutants were thawed from frozen stocks, diluted to the desired 198 
concentration in pyrogen-free saline (PFS), and administered via the intranasal route (i.n.). A 199 
sample of the inoculum was diluted appropriately, plated out on TSA and incubated overnight 200 
at 37°C to confirm the actual inoculation dose.  For each infection, mice were anaesthetised 201 
intraperitoneally (i.p.) with a combination of Ketamine (50 mg/kg; Ketalar, Pfizer Itd, Kent, UK) 202 
and Xylazine (10 mg/kg; Rompun; Berkshire, UK) diluted in PFS.  Each mouse was weighed 203 
and the volume of anaesthetic given was adjusted accordingly.  Once mice were 204 
anaesthetised, the inoculum was administered by slowly pipetting a total of 50 μl into both 205 
nostrils.  Mice were then held upright for 30 sec to ensure the liquid had passed into the lungs 206 
and were monitored until they had fully recovered from the anaesthetic.  In all cases mice 207 
were checked   at least daily for signs of illness, and if determined to have reached the 208 
humane end point specified in the Project Licence, were culled. 209 
Tissue culture infections 210 
A549 human lung epithelial cells were grown in F12-K tissue culture medium supplemented 211 
with 10% fetal bovine serum (FBS), and J774 mouse macrophages were cultured in 212 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS. For invasion and 213 
intracellular growth assays, 2x105 cells were seeded into 24-well tissue cultures dishes and 214 
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allowed to adhere for 16 hours. The cells were then washed with PBS and inoculated with 215 
2x106 CFU of wild-type B. pseudomallei or one of the TraDIS mutants in 1 mL of DMEM. The 216 
infection was allowed to proceed for one hour, at which point the media was removed, the 217 
cells washed with PBS, and 1 mL fresh DMEM or F12-K media containing 200 ⌡g/mL of 218 
kanamycin was added to the wells. The cells were incubated with antibiotics for 2 hours at 219 
37°C. For invasion assays, the cells were then lysed immediately with 0.1% Triton-X100 and 220 
10-fold dilutions were plated out onto LB agar to determine how many cells were internalized. 221 
For intracellular growth assays, the infections were allowed to proceed for 6-24 hours, at 222 
which point the cells were lysed and CFUs plated as described.  223 
Immunofluorescence 224 
J774A mouse macrophages were seeded onto glass coverslips in 6-well tissue cultures 225 
plates at a concentration of 105 CFU/mL and infected with Burkholderia strains as described 226 
above. At 24 hours post-infection, the cells were washed twice with PBS, and fixed with 4 % 227 
paraformaldehyde overnight at 4°C. The fixed cells were then washed again with PBS, 228 
permeabilized with 0.5 % Triton X-100, and blocked for 1 hour at 37°C with 5 % FBS. The 229 
cover slips were then incubated with a 1:1000 dilution of MAb CC6 (Jones et al., 2002) for 1 h 230 
at 37°C, washed 3 times in PBS for 5 minutes each, and then incubated again with a 1:10000 231 
dilution of Alexafluor488-conjugated anti-mouse secondary antibody antibody (Molecular 232 
Probes) and Alexafluor555-phalloidin conjugate solution (Molecular Probes) for 1 hr at 37°C. 233 
The cells were then again washed 3 times for 5 minutes in PBS to remove unbound 234 
antibodies and stained with DAPI (Molecular Probes) according to manufacturer’s instructions 235 
before the coverslips were mounted onto glass slides using DPX mounting medium. Samples 236 
were analyzed using a CCD fluorescence microscope (Axioplan 2 upright microscope). 237 
Serum survival assays 238 
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Wild-type B. pseudomallei and the TraDIS mutant strains were incubated with 30% pooled 239 
NHS or heat-inactivated (HI) serum in PBS at 37°C for 2 hours. HI serum was prepared by 240 
incubating the NHS at 56°C for 1 hour. Following serum exposure, the samples were serially 241 
diluted and plated onto LB agar to determine viable bacteria counts. 242 
 243 
RESULTS 244 
Identification of novel B. pseudomallei K96243 genes important for growth and survival 245 
in vivo 246 
We previously identified 39 B. pseudomallei mutants that were unable to grow and/or 247 
disseminate in an in vivo murine infection model using a signature tagged mutagenesis (STM) 248 
screen (26). Pools of 96 mutants were used to infect BALB/c mice via the intranasal route and 249 
mutants that were negatively selected in lungs and spleens were identified using microarrays 250 
directed against the unique tag on each mutant. However, due to the difficulty of identifying 251 
the transposon insertion site of each mutant with this method, only the most strongly 252 
attenuated mutants as visualized by microarray were selected to determine the nature of the 253 
mutation and verify the attenuated phenotype. We hypothesized that by applying the recently 254 
developed TraDIS sequencing technique we could quickly and easily extract additional 255 
information regarding B. pseudomallei pathogenesis from the archived bacterial genomic 256 
DNA samples from this STM screen without the requirement to undertake additional animal 257 
infections. We predicted that this method could identify additional mutants involved in 258 
pathogenesis, including those with more subtle effects acting at different stages of infection. 259 
To prepare TraDIS sequencing libraries, we pooled the archived genomic DNA samples from 260 
each input pool to create an input sample representing the entire library. As each original pool 261 
of 96 mutants was assayed through two mice, one mouse from each pool was combined to 262 
produce biological duplicate lung and spleen output pools. We then applied the TraDIS 263 
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sequencing technique and compared the input and output pools using a fold-change analysis. 264 
This improved method allowed us to gather information on every individual mutant within the 265 
library and determine whether they were negatively selected, positively selected, or 266 
unchanged between input and output pools.  267 
To identify mutants that were negatively selected in the mouse lung and spleen 268 
samples, we used a previously described quantification method (29). The total number of 269 
sequencing reads matched to each gene in the library were converted using an arcsine-root 270 
transformation and log2 fold change values between input and lung and input and spleen 271 
pools were calculated to determine the fitness of each mutant in terms of its ability to colonize 272 
within lung tissue and disseminate to and colonize the spleen. To define attenuation, we set a 273 
cut-off of the 2.5% most attenuated mutants in the spleen and the 5% most attenuated 274 
mutants in the lung based on the mean distribution of the log2 fold change. This resulted in a 275 
list of 129 mutants that were negatively selected in mouse spleen samples representing 276 
approximately 10% of the library of 1248 mutants screened (Table S1). Nine of these mutants 277 
were also strongly negatively selected in the mouse lung despite being inoculated through an 278 
intranasal route, indicating an inability to survive in that tissue. None of the mutants screened 279 
in our experiment were positively selected by our statistical cut-offs. The original 39 mutants 280 
previously identified using STM mapped to 23 different genes, all of which were also identified 281 
as negatively selected by the TraDIS method. The majority of these genes were among the 282 
most strongly negatively selected, with 20 of the 23 genes found within the cut-off we selected 283 
of the top 2.5% of log2 ratios. The three remaining transposon mutations mapped either to 284 
intergenic regions or to sequences that matched more than one gene, and thus were unable 285 
to be confirmed. Six of the genes identified by STM, wcbC, wcbJ, wcbN, gmhA, aroB, and 286 
vacJ had previously been independently confirmed to be attenuated for growth and survival in 287 
individual intranasal infections of BALB/c mice  (J. Lim et al., unpublished data). This confirms 288 
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the ability of our screen to identify attenuated B. pseudomallei mutants and serves as further 289 
proof of principle of the TraDIS assay  290 
Confirmation of attenuated TraDIS mutant phenotypes with unmarked deletion mutants 291 
 Five genes identified as negatively selected in the spleen output pools, some of which 292 
were also negatively selected in the lungs, were selected for further characterization based on 293 
strength of phenotype and predicted functional domains. Bpsl1527, which encodes the 294 
transcription accessory protein Tex, was selected because this mutant demonstrated one of 295 
the strongest attenuated phenotypes in both lung and spleen output pools. Tex is required for 296 
toxin regulation in Bordetella pertussis and Clostridum perfringens and has been shown to 297 
play a role in virulence in Pseudomonas aeruginosa and Streptococcus pneumoniae (32-35). 298 
Moreover, the structure of the P. aeruginosa homolog has been solved and shown to bind 299 
DNA, suggesting that this gene is likely to function as a transcriptional regulator. Another 300 
strongly negatively selected putative transcriptional regulator, RpiR, is encoded by bpsl0629. 301 
RpiR has been demonstrated to regulate various virulence factors of Staphylococcus aureus, 302 
suggesting that this could be another conserved regulatory gene required for in vivo virulence 303 
(36). Bpsl1728 and bpss1528 both encode predicted secreted proteins, with bpss1528 being 304 
a type III secretion system secreted protein and bpsl1728 showing homology to be a secreted 305 
outer membrane porin from Bordetella pertussis. Bpsl1728 was also of interest to us for 306 
technical reasons because it is present just above the predicted threshold of detection in our 307 
input pool, which allowed us to use this gene as an indicator of the sensitivity and accuracy of 308 
our TraDIS screen. Bpss1528, which encodes the putative Type III secretion system effector 309 
protein BapA was selected because although the B. pseudomallei T3SS-3 is known to be 310 
required for virulence, studies with this mutant in a hamster model did not display any survival 311 
phenotype, suggesting that our TraDIS assay may be able to pick up moderately attenuated 312 
mutants that would be missed in other screening methods (37) Finally, bpsl2248 was selected 313 
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for further characterization because it encodes a putative glycosyltransferase that is not 314 
associated with any of the previously characterized polysaccharide loci in B. pseudomallei. 315 
Our previous STM screen and a number of additional studies have indicated the importance 316 
of polysaccharides to B. pseudomallei virulence (26, 38).  317 
 To absolutely confirm the attenuated phenotypes of each of these mutants and 318 
address the possibility of polar effects, clean unmarked deletion mutants were constructed for 319 
each gene as has been described previously (Logue et al., 2009). Briefly, a suicide plasmid 320 
containing a null allele consisting of the upstream and downstream flanking regions of the 321 
gene of interest was introduced via homologous recombination with chloramphenicol 322 
selection. A second recombination event was then selected for with sacB-mediated counter 323 
selection against sucrose sensitivity, and the resulting colonies were screened by PCR for 324 
loss of the wild-type allele. Each mutant was then verified by Illumina whole genome 325 
sequencing to confirm the expected deletion of each gene of interest and to ascertain that no 326 
secondary mutations had occurred. Three of the genes selected for mutagenesis, bapA, rpiR, 327 
and bpss2248 are located within predicted operons, while tex and bspl1728 do not have any 328 
downstream genes located within the same reading frame (39). Due to the nature of our 329 
mutagenesis strategy, we did not expect to see polar effects from any of the mutants we 330 
constructed, including those for genes within operons. However, to be certain that 331 
transcription of downstream genes was not affected by mutagenesis, we performed RT-PCR 332 
analysis of each gene within the operons of our genes of interest and the nearest genes to tex 333 
and bspl1728 and found that transcription was not affected for any of the genes tested 334 
(Supplemental Figure 1).  335 
 The resulting deletion mutants, Δtex, ΔrpiR, Δ1728, Δ2248, and ΔbapA were each 336 
used to infect Balb/c mice via an intranasal route alongside five mice infected with wild type B. 337 
pseudomallei K96243. Colony forming units (CFUs) were plated from the inocula to determine 338 
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the exact infectious dose, and the infections were allowed to proceed for 48 hours to match 339 
the time point of the original screen. At this point lungs and spleens from each mouse were 340 
harvested, homogenized, and plated for CFUs. Four of the mutants, Δtex, ΔrpiR, Δ1728, and 341 
Δ2248, demonstrated significantly reduced CFUs in mouse spleens compared to wild-type B. 342 
pseudomallei. The Δtex mutants displayed the strongest attenuation within the spleen and 343 
also displayed strong attenuation within the lung, consistent with the TraDIS screen 344 
predictions. The remaining mutant, ΔbapA showed slightly reduced CFUs compared to wild-345 
type, but this decrease was not statistically significant (Figure 1). These results showed that 346 
the TraDIS screen was not only able to identify genes important for growth and survival in a 347 
mouse model, but was able to do so in a semi-quantitative manner and predict the relative 348 
strength of phenotype.  349 
B. pseudomallei Δtex mutants are highly attenuated and protect against challenge with 350 
wild-type B. pseudomallei 351 
 We next tested each TraDIS mutant in a survival assay to determine if the reduced 352 
CFUs seen in lung and spleen tissues correlated with decreased virulence. Interestingly, 353 
ΔrpiR, Δ1728, Δ2248, and ΔbapA demonstrated similar survival phenotypes to wild-type B. 354 
pseudomallei at an infectious dose of approximately 103 CFU despite significant reduction of 355 
bacterial CFUs in the spleen. This suggests that the sensitivity of our TraDIS assay allowed 356 
the identification of mildly attenuated phenotypes below the threshold of attenuation that 357 
would lead to a decrease in virulence as defined by survival. Supporting this hypothesis, the 358 
mutant with the strongest TraDIS phenotype, Δtex, showed increased mouse survival 359 
compared to wild-type bacteria, with over 80% long-term survival (Figure 2a). To determine if 360 
the surviving animals had completely cleared the infection with the Δtex mutant, we plated 361 
CFUs from four of the remaining mice at 60 days post-infection. We found that all four mice 362 
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retained Δtex CFUs within the spleen, while only half of the mice had CFUs above the level of 363 
detection within the lungs (Figure 2b). 364 
 Since Δtex proved to be attenuated in the acute model of infection, we sought to 365 
examine whether it is able to confer protection against subsequent challenge with virulent 366 
wild-type B. pseudomallei. Five weeks after intranasal challenge with either saline or Δtex, 367 
Balb/c mice were challenged with approximately 1000 CFU of B. pseudomallei K96243 and 368 
survival was monitored. Our data indicate that Δtex is able to provide protection in the acute 369 
model of infection (Figure 2c), resulting in significantly increased time to death. Analysis of 370 
organ CFU from surviving mice revealed the retention of wild-type bacteria in both the lung 371 
and spleen (Figure 2d) and splenomegaly in a minority of cases (data not shown). However, 372 
in contrast to challenge with Δtex, none of the surviving mice demonstrated retention of the 373 
Δtex mutant in lung or spleen (data not shown). 374 
Δtex, ΔrpiR, Δ1728, and ΔbapA display decreased intracellular survival, but are able to 375 
complete the intracellular life cycle 376 
 B. pseudomallei is considered a facultative intracellular pathogen, but is highly 377 
resistant to killing by human sera and is able to survive and replicate extracellularly. We were 378 
interested in determining how large a role, if any, intracellular survival and replication played 379 
in the attenuated phenotypes of the TraDIS mutants. As B. pseudomallei is able to induce its 380 
own uptake into epithelial cells (9), we first analyzed invasion of A549 human lung epithelial 381 
cells by infecting a monolayer of cells with a multiplicity of infection (MOI) of 10 CFU of Δtex, 382 
ΔrpiR, Δ1728, Δ2248, ΔbapA, or wild type B. pseudomallei K96243 per cell and allowed the 383 
infection to proceed for one hour. The cells were then gently washed and kanamycin was 384 
added to the media to kill any remaining extracellular bacteria. At 2 hours post-infection, the 385 
cells were lysed and plated to determine the number of intracellular CFU. Intracellular 386 
bacteria were present for every condition tested, and none of the mutants appeared to be 387 
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internalized differently than wild-type bacteria, suggesting that they do not have defects 388 
related to adhesion or invasion of host cells (Figure 3a).  389 
 We next analyzed whether the TraDIS mutants were able to survive and replicate 390 
within A549 lung epithelial cells. We found that at 18 hours post-infection Δ1728 and Δ2248 391 
replicated to similar levels as wild-type B. pseudomallei, while ΔrpiR and ΔbapA showed 392 
reduced intracellular CFUs. The most highly attenuated mutant, Δtex, demonstrated 393 
significantly reduced levels of intracellular bacteria, suggesting that this mutant is either killed 394 
by intracellular immune responses such as autophagy or is not capable of completing the 395 
intracellular life cycle (Figure 3b). As B. pseudomallei is also capable of replicating within 396 
professional phagocytes suchas macrophages, we also analyzed intracellular survival within 397 
J774 mouse macrophage cells. We found that at 16 hours post-infection all of the mutants 398 
with decreased CFUs within A549 cells were also attenuated within J774 cells. Interestingly, 399 
the mutant Δ1728, which showed comparable intracellular growth and survival to wild-type B. 400 
pseudomallei in A549 cells demonstrated reduced bacterial load in J774 cells, suggesting 401 
susceptibility to innate immune killing mechanisms rather than intracellular survival (Figure 402 
3c). 403 
 To determine whether the attenuated phenotypes of the TraDIS mutants is due to an 404 
impaired intracellular life cycle, we analyzed the ability of each mutant to escape from the 405 
phagocytic vacuole, polymerize actin to become motile within the host cell cytoplasm, and 406 
form multinucleated giant cells (MNGCs) by fusing the infected host cell with neighboring 407 
cells. At six hours post infection we found that each of the TraDIS mutants was present in the 408 
host cell cytoplasm and could be seen to polymerize actin comet tails that allow the bacteria 409 
to extrude out of the host cell (Figure 4). Moreover, despite the decreased levels of bacteria 410 
within the host cells, each mutant was also able to form MNGCs, showing that they are 411 
capable of spreading from cell to cell and inducing cell fusion (data not shown). This suggests 412 
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that none of the TraDIS mutants are blocked at any stage of the intracellular life cycle, but 413 
rather are less capable of surviving intracellularly and/or have a delayed life cycle.  414 
Δ1728 and Δ2248 are sensitive to killing by human sera 415 
 We next tested if the TraDIS mutants are resistant to killing by human serum. B. 416 
pseudomallei has been shown to be highly resistant to complement-mediated killing and 417 
complement deposition, and is capable of surviving within human sera. We found that while 418 
ΔTex, ΔrpiR, and ΔbapA are also fully resistant to human sera, both Δ1728 and Δ2248 show 419 
reduced survival in 30% pooled normal human sera (NHS) compared to PBS. This suggests 420 
that extracellular survival may play a role in the attenuation of at least two of the TraDIS 421 
mutants, and that our TraDIS screen is capable of identifying attenuated mutants with more 422 
than one phenotype.  423 
 424 
DISCUSSION 425 
TraDIS sequencing technology has previously been demonstrated to be useful for 426 
mining new data from archived experimental samples . While the microarray-based method 427 
used in STM screens relies on hybridization of fluorescent probes and is thus only semi-428 
quantitative, TraDIS can quantitate the number of sequencing reads that match to each gene 429 
in every pool, allowing a statistical comparison (Table S1)(27, 29). We were able to re-430 
analyze our archived STM samples using TraDIS and identify over 100 new attenuated 431 
mutants as well as provide fitness information for every mutant screened without the need for 432 
additional animal experiments. This demonstrated the sensitivity and value of the TraDIS 433 
technology over other screening techniques and identified novel virulence factors for future 434 
characterization. By comparing the TraDIS and STM data we also noticed that the STM 435 
analysis was biased towards identifying genes which were heavily represented in the input 436 
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pool, while the TraDIS analysis gave us information on every mutant regardless of how 437 
abundant they were in the library.  438 
Our TraDIS screening method successfully identified the 23 genes previously 439 
determined to be attenuated in our STM screen, providing a proof of principle for the TraDIS 440 
screening method and validating our STM data. In both screens, the majority of the 441 
attenuation mutants were negatively selected only in mouse spleens, while a minority were 442 
attenuated in both spleens and lungs. This is most likely a consequence of the intranasal 443 
route of infection used for these experiments, as dissemination to other tissue types 444 
represents a more extreme selection than survival and replication within the tissue that was 445 
directly inoculated. In addition to those described in this manuscript, a number of the mutants 446 
identified in both our STM and TraDIS screens have since been individually tested and 447 
confirmed to be attenuated following the initial screen, which further validates both screening 448 
methods. These include mutants in multiple genes within the bacterial capsule locus which 449 
have since been further characterized to clarify their role in capsule biosynthesis . In addition, 450 
both aroB (bpsl3168) and vacJ (bpsl3147) mutants have been independently confirmed to 451 
have delayed mean time-to-death and decreased CFU phenotypes compared to wild-type B. 452 
pseudomallei (J. Lim et al., unpublished data).  453 
Among the genes newly identified as negatively selected by TraDIS were multiple 454 
genes that been previously demonstrated to be involved in virulence in B. pseudomallei and 455 
in other species of bacteria. These include the genes flgK and fliN, which are associated with 456 
flagella biosynthesis and function, the thiol peroxidase tpx, which mediates resistance to 457 
oxidative stress the shikimate dehydrogenase aroE (40-43). A number of metabolic genes 458 
and transcriptional regulators were also identified, suggesting that B. pseudomallei K96243 459 
must adapt its metabolic functions in an in vivo environment in order to be a successful 460 
pathogen. In addition, multiple mutants in putative glycosyltransferases (bpss2167, bpss2148, 461 
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bpsl1444) were identified as negatively selected, suggesting a role for polysaccharides other 462 
than the capsule in virulence. Furthermore, many of the novel B. pseudomallei genes that 463 
were identified in our negative selection screen have been shown to play a role in virulence in 464 
the closely related species P. aeruginosa, including the tryptophan synthesis genes trpB, 465 
trpE, and trpF as well as the methyltransferase hemK(44, 45). Many of the other genes 466 
identified were hypothetical proteins or genes that have not yet been shown to play a role in 467 
bacterial virulence.  468 
A number of the newly identified attenuated mutants are putative polysaccharide 469 
biosynthesis genes including bpss2167, bpsl1444, and bpss2248. The B. pseudomallei 470 
genome encodes four large polysaccharide loci all of which have been demonstrated to play a 471 
role in virulence in vivo; the type I O-PS capsule, the type II O-PS LPS, and two additional 472 
clusters defined as type III O-PS and type IV O-PS . However, the genes identified in our 473 
screen do not belong to any of these clusters, which suggest that the role of polysaccharides 474 
in B. pseudomallei infections is even more complex than has been previously described. 475 
Bpss2167 and bpss2248 both encode predicted glycosyltransferases belonging to 476 
glycosyltransferase family 2, but their specific roles are unknown. Bpsl1444 shows similarity 477 
to the glycotransferase waaG. This is notable because many of the other waa genes, which 478 
are involved in the biosynthesis and construction of the core sugar of the B. pseudomallei 479 
LPS, were identified as essential genes (28). It would be of interest in future experiments to 480 
determine if bpsl1444 plays a role in virulence due to being important to the structural integrity 481 
of the bacterium or if this phenotype is due to compromised LPS.  482 
It is interesting to note that of the five mutants characterized in this study, all but one 483 
displayed some level of intracellular attenuation in at least one cell line. This is not 484 
unexpected as B. pseudomallei is considered to be a facultative intracellular pathogen, but is 485 
notable because many of the best-studied B. pseudomallei virulence factors are genes 486 
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associated with the capsule, LPS, and flagella, which all play a role in extracellular, rather 487 
than intracellular, survival (26, 38, 46). Moreover, the majority of B. pseudomallei genes that 488 
have been implicated in intracellular growth and survival, such as  BimA and the Bsa Type III 489 
secretion system, have been demonstrated to interfere with at least one stage of the 490 
intracellular life cycle (13, 16). This suggests that the mutants described here represent a 491 
class of virulence factors required for intracellular survival rather than subjugation of the host 492 
cell to complete the bacterial life cycle. A similar class of virulence factors was identified in an 493 
in vitro screen for B. pseudomallei mutants that failed to form plaques on cell monolayers by 494 
Pilatz et al., and it is interesting to note that one of the 9 genes identified in their screen, 495 
purM, was also identified in our assay (Table S1)(47). It is likely that the TraDIS screen was 496 
able to identify this class of mutants in an in vivo model because this technique is capable of 497 
following mild attenuation phenotypes that would otherwise be overlooked in screens that 498 
focus on animal survival and/or host cell death.  499 
Of the mutants characterized in this work, only Δtex displayed a degree of attenuation 500 
both in vivo and in vitro that is comparable to the mutants identified in our original STM 501 
screen. It is likely that this mutant was missed in the STM screen only because it is less highly 502 
represented in the input pool compared to the capsule mutants, making the difference 503 
between input and output pools less obvious by microarray analysis (Table S1). Tex has been 504 
shown to play an important role in virulence in both B. pertussis and S. pneumoniae, but the 505 
exact nature of this role appears to differ between species as Tex regulates toxin expression 506 
in B. pertussis but not S. pneumoniae (32, 33). As Tex is predicted to be a transcription factor 507 
and has been shown to bind DNA in both S. pneumoniae and P. aeruginosa (33, 34), it will be 508 
interesting to determine the transcriptome of this gene in B. pseudomallei and determine if 509 
Tex regulates toxin expression or other known virulence factors. Moreover, since the 510 
protection provided by Δtex mutants is comparable to other B. pseudomallei mutants that 511 
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have been investigated as live vaccine candidates, so it will be interesting to further 512 
investigate the potential of Δtex vaccine candidates (25). Transposon mutant screens have 513 
historically been successful at identifying both major virulence factors and potential live 514 
vaccine candidates, and the identification of B. pseudomallei Tex demonstrates that TraDIS 515 
can be used to identify such genes that may have been missed in previous screening 516 
methods, as well as to identify mutants with mild virulence phenotypes that can provide new 517 
insight into aspects bacterial pathogenesis that would otherwise be overlooked.  518 
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 678 
  679 
Figure 1. TraDIS mutants show reduced bacterial burdens in infected Balb/c mice 680 
Balb/C mice (n = 5) were infected intranasally with either B. pseudomallei K96243 or the 681 
individual deletion mutant indicated. At 48 hours post-infection spleens and lungs were 682 
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harvested from the infected animals and bacterial loads were determined. Lines indicated 683 
mean and standard error for each sample. Statistical significance was determined using the 684 
Mann-Whitney test with p values indicated above each sample. ns = not significant. Mice 685 
infected with (A) 500 CFU of K96243 or ΔRpiR (spleen, p=0.0079) (B) 500 CFU of K96243 or 686 
800 CFU of ΔBapA (ns) (C) 1x103 CFU of K96243 or Δ1728 (lungs, p=0.0317; spleen 687 
p=0.0159) (D) 1x103 CFU of K96243 or Δtex (lungs, p=0.0079; spleen p=0.0079), and (E) 688 
2x103 CFU of K96243 or Δ2248 ( lungs ns, spleen, p=0.0317) 689 
 690 
Figure 2. Survival of Balb/C mice following infection with TraDIS mutants 691 
(A) Balb/C mice (n=5) were infected with 103 CFU of K96243, Δ1728, or ΔTex. The median 692 
survival for K96243 was 2.5 days post infection, while the median survival for Δ1728 was 3 693 
days post infection 4 out of 5 mice infected with Δtex were still alive when the experiment was 694 
terminated at 60 days post-infection. The survival of both mutants was statistically 695 
significantly different from wild-type as determined by Log-rank (Mantle-Cox) test with p 696 
values of 0.0449 and 0.0009 respectively. (B) The bacterial load in mice infected with Δtex 697 
was determined in surviving mice at 60 days post infection. All four mice displayed detectable 698 
levels of B. pseudomallei Δtex in the spleen, while only two animals had detectable CFUs in 699 
the lungs. (C) Balb/C mice were vaccinated with either 103 CFU Δtex or a saline control and 700 
challenged intranasally with 103 CFU wild-type B. pseudomallei at 5 weeks post-vaccination.  701 
Survival up to 80 days post-challenge is shown, with the Δtex vaccinated animals showing a 702 
statistically significantly different mean time-to-death of 31 days compared to 6 days for saline 703 
vaccinated animals (p<0.001). (D) At 80 days post-challenge, surviving Δtex-vaccinated mice 704 
were sacrificed and lungs and spleens were harvested and plated to determine if the bacteria 705 
had been cleared from the animals. All colonies isolated from both organs were determined to 706 
be wild-type B. pseudomallei by PCR screening.  707 
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 708 
Figure 3. Internalization, growth, and survival of TraDIS mutants in cultured cells 709 
(A) The B. pseudomallei TraDIS mutants are all able to induce their own uptake into A549 710 
human lung epithelial cells. Cells were infected at a MOI of 10 for 1 hr, then washes and 711 
overlayed with 400 μg/mL kanamycin. At 2 hours post-infection cells were lysed and the 712 
bacterial loads determined. None of the mutants displayed statistically significantly different 713 
bacterial CFU compared to wild-type as determined by ANOVA. (B) The B. pseudomallei 714 
TraDIS mutants show variable growth and survival in A549 cells. Cells were infected with a 715 
MOI of 1, and the infection was allowed to proceed for 18 hours. ΔRpiR, ΔBapA, and Δtex all 716 
had statistically significantly decreased bacterial loads as determined by Mann-Whitney test 717 
with p values of p=0.0005, p<0.00001, and p<0.00001 respectively. (C) The B. pseudomallei 718 
TraDIS mutants show variable growth and survival in J774 murine macrophages. Cells were 719 
infected with a MOI of 1, and the infection was allowed to proceed for 16 h. ΔRpiR, ΔBapA, 720 
and Δtex all had statistically significantly decreased bacterial loads as determined by Mann-721 
Whitney test with p values of p=0.0045, p=0.0078, and p=0.0002 respectively. Interestingly, in 722 
this cell line Δ1728 also showed reduced bacterial load compared to wild-type (p=0.0019). 723 
 724 
Figure 4. All B. pseudomallei TraDIS mutants can polymerize actin 725 
J774 murine macrophages were infected with either (A) B. pseudomallei K96243, (B) ΔRpiR, 726 
(C) ΔBapA, (D) Δ1728, (E) Δtex and (F) Δ2248 at an MOI of 10. After four hours, cells were 727 
fixed and stained with the CC6 monoclonal antibody against B. pseudomallei LPS (green) and 728 
phalloidin (red) which stains actin filaments. Actin comet tails (blue arrows) were visible in all 729 
samples, indicating that the B. pseudomallei mutants are capable of entering cells and 730 
escaping into the cytoplasm where they are able to polymerize actin to spread cell-to-cell.  731 
 732 
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Figure 5. Sensitivity of B. pseudomallei TraDIS mutants to human sera 733 
 106 CFU of B. pseudomallei K96243 wild-type, ΔRpiR, ΔBapA, Δ1728, Δtex, and Δ2248 were 734 
incubated with either 30% natural human serum (NHS), 30% heat inactivated NHS, or PBS 735 
control for 2 hr at 37° C. While wild-type, ΔRpiR, ΔBapA, and Δtex were resistant to killing by 736 
human sera as has been previously reported for B. pseudomallei K96243, Δ1728 and Δ2248 737 
were both sensitive to complement killing by human sera (p value 0.0029 and 0.0000056 738 
respectively).  739 
 740 
 741 
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